Hemab Therapeutics (NASDAQ:COAG) Posts Earnings Results

Hemab Therapeutics (NASDAQ:COAG) released its earnings results on Thursday. The company reported ($23.98) earnings per share for the quarter, Zacks reports.

Hemab Therapeutics Stock Performance

COAG stock opened at $26.47 on Thursday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $36.61.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the acquisition, the director owned 6,149,096 shares in the company, valued at $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased 2,898,074 shares of company stock valued at $53,650,008 in the last 90 days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.